Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prolyl 3-hydroxylase family member 4 (P3H4) is an endoplasmic reticulum (ER)-resident protein and a member of the Leprecan family, also known as endoplasmic reticulum protein SC65[2]. Unlike other prolyl 3-hydroxylases, P3H4 is believed to lack enzymatic activity and instead functions as a regulatory or structural component in collagen modification complexes[2]. It has been shown to be a direct substrate of the ER-phagy receptor CCPG1, which mediates selective removal of aberrant ER proteins[2]. P3H4 forms complexes with enzymes involved in collagen maturation, particularly influencing the hydroxylation of collagen lysine residues via complex formation with other prolyl 3-hydroxylases[2]. Studies indicate that P3H4 is linked to cancer biology; its overexpression correlates with poor prognosis and increased tumor progression in bladder and lung cancers[2]. Currently, P3H4 is not recognized as a druggable enzyme, receptor, or transporter, and there are no known approved drugs or small molecules that directly interact with it or target it therapeutically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prolyl 3-hydroxylase family member 4 (P3H4).